瑞戈非尼
索拉非尼
癌症研究
Wnt信号通路
肝细胞癌
血管内皮生长因子
医学
PI3K/AKT/mTOR通路
信号转导
内科学
肿瘤科
生物信息学
癌症
生物
血管内皮生长因子受体
细胞生物学
结直肠癌
作者
Sadaf Altaf,Faiza Saleem,Azam Ali Sher,Asad Ali
出处
期刊:Current Molecular Pharmacology
[Bentham Science]
日期:2022-12-01
卷期号:15 (7): 929-942
被引量:1
标识
DOI:10.2174/1874467215666220103111009
摘要
Abstract: Hepatocellular carcinoma (HCC) is a complex, life-threatening and most common neoplasm in the world. HCC tumors are genetically and phenotypically heterogeneous, and involve various molecular mechanisms and stimulation of several signaling pathways, such as Vascular Endothelial Growth Factor, Epidermal Growth Factor Receptors (EGFR), Insulin growth factor, Ras/extracellular signal-stimulated kinase, the mammalian goal of rapamycin (mTOR), c-mesenchymal- epithelial transition factor-1 (c-Met), Hedgehog, Wnt and apoptotic signaling. Lately, in patients, multi-kinase cascade blockers, such as sorafenib, selumetinib and regorafenib, have increased the survival rate of progressive HCC. This development presents a step forward towards the therapy of liver cancer infection and attests that molecular systemic rehabilitation can be useful in HCC treatment. The development of these systemic therapeutic agents has further expanded the research area for surplus molecular mediators to auxiliary increase the cure rate of patients. This article reviews the complete focus on cascades, current enduring clinical tests by means of HCC therapeutic mediators, and imminent prospects in the cure of HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI